Management of venous thrombosis and pulmonary embolism after gynecological surgery.

abstract：:Rivaroxaban is approved in Europe and the United States for thromboprophylaxis following total joint arthroplasty. As the rate of obesity increases, confirming safety and efficacy in this patient population is paramount. This retrospective chart review assessed the efficacy and safety of rivaroxaban between two body m...

journal_title：Seminars in thrombosis and hemostasis

authors： Krauss ES,Cronin M,Dengler N,Simonson BG,Altner K,Daly M,Segal A

更新日期：2019-03-01 00:00:00

abstract：:In the pathogenesis of vascular disease, inflammation and coagulation play a pivotal role. Increasing evidence points to an extensive cross-talk between these two systems, whereby inflammation not only leads to activation of coagulation, but coagulation also considerably affects inflammatory activity. Tissue factor (T...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,van der Poll T,ten Cate H

更新日期：2006-02-01 00:00:00

abstract：:Currently, in Germany, there is a successful program where patients monitor their own coagulation status through self-testing. The advent of a new generation of coagulometers has allowed more and more patients to use self-testing to monitor their coagulation status. The development of a structured training program by ...

journal_title：Seminars in thrombosis and hemostasis

authors： Taborski U,Müller-Berghaus G

更新日期：1999-01-01 00:00:00

abstract：:Trauma remains one of the major causes of death and disability all over the world. Uncontrolled blood loss and trauma-induced coagulopathy represent preventable causes of trauma-related morbidity and mortality. Treatment may consist of allogeneic blood product transfusion at a fixed ratio or in an individualized goal-...

journal_title：Seminars in thrombosis and hemostasis

authors： Stein P,Kaserer A,Spahn GH,Spahn DR

更新日期：2017-06-01 00:00:00

abstract：:Protein C inhibitor (PCI) is a serine protease inhibitor and was originally identified as an inhibitor of activated protein C (APC). However, PCI is not specific for APC and also inhibits several proteases involved in coagulation, fibrinolysis, cancer, wound healing, and fertility. The biological function of PCI is un...

journal_title：Seminars in thrombosis and hemostasis

authors： Meijers JC,Herwald H

更新日期：2011-06-01 00:00:00

abstract：:These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

journal_title：Seminars in thrombosis and hemostasis

authors： Hiebert L,Liu JM

更新日期：1991-01-01 00:00:00

abstract：:Biological rhythms are a universal phenomenon in living organisms and serve to help organisms adapt within a circadian cycle to the 24-hour-oscillating environment. The rhythmic modulation of selective pathways thus enables organisms to optimize their ability to store and generate chemical energy, to minimize environm...

journal_title：Seminars in thrombosis and hemostasis

authors： Montagnana M,Salvagno GL,Lippi G

更新日期：2009-02-01 00:00:00

abstract：:A simple RIA method for B beta 15-42 RPs has been evaluated in our laboratory to investigate experimental and clinical fibrinolytic states. The assay utilizes bentonite precipitation to remove cross-reacting fibrinogen. Due to the heterogeneity in molecular weights of the B beta RPs, the results are expressed as nanog...

journal_title：Seminars in thrombosis and hemostasis

authors： Walenga JM,Fareed J,Mariani G,Messmore HL Jr,Bick RL,Emanuele RM

更新日期：1984-10-01 00:00:00

abstract：:Defective systemic fibrinolysis and articular persistence of fibrinlike material are well recognized in RA. Perturbation of the major plasma protease inhibitors, A1AT, A2MG, and AT III, was explored in RA, psoriatic arthritis, and Reiter's syndrome. Experimental evidence is presented and assessed with respect to the p...

journal_title：Seminars in thrombosis and hemostasis

authors： Rothschild BM,Thompson LD,Pifer DD,Chesney CM

更新日期：1985-10-01 00:00:00

abstract：:Although the current therapeutic armamentarium of venous thrombosis encompasses the use of vitamin K antagonists, heparins, and direct oral anticoagulants, these drugs have several important drawbacks. Antisense oligonucleotides are relatively short single-stranded nucleic acid sequences, which hybridize with a target...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Harenberg J,Mattiuzzi C,Favaloro EJ

更新日期：2015-03-01 00:00:00

abstract：:Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder with potentially life-threatening consequences. FXIII is composed of two subunits (A and B), and a deficiency or dysfunction of either can result in FXIII deficiency. Traditionally, FXIII deficiency has been managed by infusing ...

journal_title：Seminars in thrombosis and hemostasis

authors： Carcao M,Fukutake K,Inbal A,Kerlin B,Lassila R,Oldenburg J,Garly ML,Nugent D

更新日期：2017-02-01 00:00:00

abstract：:To elucidate the mechanisms by which hematopoietic progenitor cells selectively lodge in bone marrow, we established endothelial cell lines derived from bone marrow and lung and then examined the transendothelial migration of hematopoietic progenitor cells by using cells was examined by a Transwell migration assay. He...

journal_title：Seminars in thrombosis and hemostasis

authors： Imai K,Kobayashi M

更新日期：1998-01-01 00:00:00

abstract：: ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2019-02-01 00:00:00

abstract：:In the early 1980s, the first external quality assessment schemes (EQAS) regarding parameters of the coagulation laboratory were established in the daily routine of German laboratories. At present, the EQAS performed by INSTAND offers a wide range of global and single parameters of thrombosis and hemostasis. Only the ...

journal_title：Seminars in thrombosis and hemostasis

authors： Spannagl M,Dick A,Reinauer H

更新日期：2007-04-01 00:00:00

abstract：:The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortalit...

journal_title：Seminars in thrombosis and hemostasis

authors： Zadow EK,Wundersitz DWT,Hughes DL,Adams MJ,Kingsley MIC,Blacklock HA,Wu SSX,Benson AC,Dutheil F,Gordon BA

更新日期：2020-10-01 00:00:00

abstract：:We present the clinical characteristics of pregnancy histories and subsequent pregnancy outcomes of 13 women who tested positive for anticardiolipin beta2-glycoprotein I antibody (aCLbeta2GPI). Six of the 13 women had a history of recurrent spontaneous abortion (RSA). The prevalence of aCLbeta2GPI syndrome among women...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamada H,Kato EH,Morikawa M,Shimada S,Ebina Y,Sakuragi N,Suzuki S,Minakami H

更新日期：2003-12-01 00:00:00

abstract：:With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more comm...

journal_title：Seminars in thrombosis and hemostasis

authors： Novelli EM,Ragni MV

更新日期：2008-09-01 00:00:00

abstract：:Asymptomatic pulmonary embolism (PE) is present in at least one-third of patients with deep venous thrombosis (DVT). However, knowledge about its influence on the prognosis of patients is limited. The aim of this study was to assess the prognostic impact of asymptomatic PE in patients with DVT and to explore risk fact...

journal_title：Seminars in thrombosis and hemostasis

authors： Boc A,Vene N,Košmelj K,Mavri A

更新日期：2017-02-01 00:00:00

abstract：:von Willebrand disease (vWD) is the commonest bleeding disorder in women. More than 70% of women with vWD suffer from menorrhagia and half of them suffer from dysmenorrhea. There is also the risk of hemorrhage with ovulation and mid-cycle pain. These have a significant effect on all aspects of quality of life. vWD als...

journal_title：Seminars in thrombosis and hemostasis

authors： Kadir RA,Chi C

更新日期：2006-09-01 00:00:00

abstract：:From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

更新日期：1998-01-01 00:00:00

abstract：:Hip replacement surgery carries a high risk of thromboembolic complications, and pharmacological prophylaxis is routinely adopted in clinical practice. Meta-analyses have indicated that low molecular weight heparins (LMWHs) are clinically superior to conventional prophylaxis with unfractionated heparin. These analyses...

journal_title：Seminars in thrombosis and hemostasis

authors： Lassen MR,Backs S,Borris LC,Kaltoft-Sørenson M,Coff-Ganes H,Jeppesen E

更新日期：1999-01-01 00:00:00

abstract：:Treatment of patients with inhibitors to FVIII remains a complex clinical problem. Although characterizing the individual patient may aid in the initial development of a care plan, no treatment is uniformly reliable for all patients. Experts in the field are as likely to disagree as agree when it comes to choosing tre...

journal_title：Seminars in thrombosis and hemostasis

authors： Macik BG

更新日期：1993-01-01 00:00:00

abstract：:Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamamoto K,Takeshita K,Saito H

更新日期：2014-09-01 00:00:00

abstract：:Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have bee...

journal_title：Seminars in thrombosis and hemostasis

authors： Severin T,Zieger B,Sutor AH

更新日期：2002-10-01 00:00:00

abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

journal_title：Seminars in thrombosis and hemostasis

authors： Tabuchi N,Tigchelaar I,van Oeveren W

更新日期：1995-01-01 00:00:00

abstract：:The prothrombin time (PT) assay is the most clinically ordered coagulation test and is most often used for monitoring of vitamin K antagonist (VKA) therapy (e.g., warfarin), where results are expressed as an international normalized ratio (INR). The INR is in essence the patient's PT "mathematically adjusted" to a sta...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Adcock DM

更新日期：2008-10-01 00:00:00

abstract：:Essential thrombocythemia (ET) is a clonal myeloproliferative disorder of unknown origin primarily involving the megakaryocyte/platelet lineage. In an attempt to evaluate the role of the receptor c-mpl and its ligand thrombopoietin (TPO) in ET, various studies have been undertaken, the results of which are discussed h...

journal_title：Seminars in thrombosis and hemostasis

authors： Griesshammer M,Bangerter M,Schrezenmeier H

更新日期：1997-01-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in approximately 70 to 90% of patients when treatment includes all- TRANS retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most of...

journal_title：Seminars in thrombosis and hemostasis

authors： Tallman MS,Abutalib SA,Altman JK

更新日期：2007-06-01 00:00:00

abstract：:Anticoagulant therapy reduces deaths and disability in patients with or at risk of both arterial and venous thromboembolism. Highly effective antithrombotic therapies now exist that reduce the risk of both arterial thrombosis and venous thrombosis. Anticoagulant strategies include platelet inhibition, using a variety ...

journal_title：Seminars in thrombosis and hemostasis

authors： Goy J,Crowther M

更新日期：2012-10-01 00:00:00

abstract：:Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clin...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Hoppensteadt D,Borris LC,Lassen MR

更新日期：1991-01-01 00:00:00